论文部分内容阅读
目的:探讨疑似化脓性脑膜炎病初伴上呼吸道感染川崎病患儿用药的合理性,为临床上疑似化脓性脑膜炎表现的川崎病患儿的治疗提供参考。方法:回顾性分析1例2岁川崎病患儿的病例资料,对患儿抗感染治疗方案进行分析和评价;探讨不完全型川崎病患儿脑脊液白细胞计数异常升高的机制,并分析诊疗过程中患儿的药学监护和治疗结果。结果:患儿病初上呼吸道感染症状明显,进行抗感染治疗合理,但选用氨曲南欠妥。临床在排除化脓性脑膜炎,明确患儿川崎病诊断的前提下,及时调整用药,患儿症状好转。结论:临床应规范抗菌药物的合理应用,并高度重视不完全型川崎病患儿的脑脊液异常情况,加强临床观察,确保用药安全。
Objective: To investigate the rationality of medication for Kawasaki disease in patients with suspected purulent meningitis and early upper respiratory tract infection, and to provide reference for the treatment of Kawasaki disease in children with suspected purulent meningitis. Methods: A retrospective analysis of 1 case of Kawasaki disease in children with 2-year-old data, anti-infective treatment in children with the analysis and evaluation of programs; children with incomplete Kawasaki disease cerebrospinal fluid leukocyte count abnormal increase in the mechanism and analysis of the treatment process In children with drug monitoring and treatment results. Results: Early symptoms of respiratory tract infection in children with obvious anti-infective treatment is reasonable, but the use of aztreonam defects. Clinical exclusion of purulent meningitis, Kawasaki disease in children with a clear diagnosis of the premise, timely adjustment medication, children with symptoms improved. Conclusion: The rational application of antibacterials should be standardized in clinical practice, and abnormal cerebrospinal fluid abnormalities in children with incomplete Kawasaki disease should be attached great importance to enhance clinical observation and ensure the safety of medication.